Nova Mentis Life Science Corp. (NMLSF)
- Previous Close
0.0130 - Open
0.0130 - Bid --
- Ask --
- Day's Range
0.0130 - 0.0150 - 52 Week Range
0.0100 - 0.0400 - Volume
18,200 - Avg. Volume
44,318 - Market Cap (intraday)
2.208M - Beta (5Y Monthly) 0.68
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date May 30, 2024 - Jun 3, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Nova Mentis Life Science Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing diagnostics and psilocybin-based therapeutics for the treatment of neuroinflammatory disorders, including autism spectrum disorder and fragile X syndrome. The company was formerly known as Liberty Leaf Holdings Ltd. and changed its name to Nova Mentis Life Science Corp. in June 2020. Nova Mentis Life Science Corp. was incorporated in 2004 and is based in Vancouver, Canada.
www.novamentis.caRecent News: NMLSF
Performance Overview: NMLSF
Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NMLSF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NMLSF
Valuation Measures
Market Cap
1.61M
Enterprise Value
1.59M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
91.49
Price/Book (mrq)
--
Enterprise Value/Revenue
77.02
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-459.53%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-1.22M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
8.09k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
193.62k